Angle PLC Announces Parsortix at European Breast Cancer Conference - Seite 3

For further information:

ANGLE plc

[phone]

Andrew Newland, Chief Executive

Ian Griffiths, Finance Director

Berenberg (NOMAD and Broker)

Toby Flaux, Ciaran Walsh, Milo Bonser

[phone]

FTI Consulting

Simon Conway, Ciara Martin

Matthew Ventimiglia (US)

[phone]

[phone]

For Research Use Only. Not for use in diagnostic procedures.

For Frequently Used Terms, please see the Company's website on https://angleplc.com/investor-relations/glossary/

Notes for editors

About ANGLE plc

ANGLE is a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology using a simple blood sample. ANGLE's FDA cleared and patent protected circulating tumour cell (CTC) harvesting technology known as the Parsortix PC1 System enables complete downstream analysis of the sample including whole cell imaging and proteomic analysis and full genomic and transcriptomic molecular analysis.

ANGLE's commercial businesses are focusing on diagnostic products and clinical services. Diagnostic products include the Parsortix system and associated consumables. The clinical services business is offered through ANGLE's GCP-compliant laboratories in the UK. Services include custom made assay development and clinical trial testing for pharma.

Over 90 peer-reviewed publications have demonstrated the performance of the Parsortix system. For more information, visit www.angleplc.com

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

SOURCE: ANGLE plc

View the original press release on accesswire.com


The ANGLE Stock at the time of publication of the news with a raise of +10,53 % to 1,890USD on Nasdaq OTC stock exchange (19. März 2024, 14:31 Uhr).